Next-generation sequencing and empowering personalised cancer medicine

Drug Discovery Today

Volumn 20, Issue 12, 2015, Pages 1470-1475

  McDermott, Ultan ^a  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE INHIBITOR; IMATINIB; MICROTUBULE ASSOCIATED PROTEIN 4; PROTEIN TYROSINE KINASE INHIBITOR;

CANCER GROWTH; CANCER THERAPY; CARCINOGENESIS; CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; DNA REPAIR; DNA SEQUENCE; DOUBLE STRANDED DNA BREAK; DRUG DESIGN; DRUG RESISTANCE; GENE SEQUENCE; GENOME; HEALTH CARE COST; HOMOLOGOUS RECOMBINATION; HUMAN; INDEL MUTATION; LEUKEMIA; LUNG CANCER; MELANOMA; MISMATCH REPAIR; NEXT GENERATION SEQUENCING; PERSONALIZED MEDICINE; POINT MUTATION; PROMOTER REGION; QUALITY OF LIFE; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; GENETICS; GENOMICS; HIGH THROUGHPUT SEQUENCING; HUMAN GENOME; NEOPLASMS; PROCEDURES;

GENOME, HUMAN; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; NEOPLASMS; PRECISION MEDICINE;

EID: 84949512157     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2015.10.008     Document Type: Review

References (43)

1. M.R. Stratton, and et al. The cancer genome Nature 458 2009 719 724
2. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
3. P.B. Chapman, and et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation N. Engl. J. Med. 364 2011 2507 2516
4. A.T. Shaw, and et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N. Engl. J. Med. 368 2013 2385 2394
5. T.S. Mok, and et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N. Engl. J. Med. 361 2009 947 957
6. M.S. Lawrence, and et al. Discovery and saturation analysis of cancer genes across 21 tumour types Nature 505 2014 495 501
7. D. Tamborero, and et al. Comprehensive identification of mutational cancer driver genes across 12 tumor types Sci. Rep. 3 2013 2650
8. T.I. Zack, and et al. Pan-cancer patterns of somatic copy number alteration Nat. Genet. 45 2013 1134 1140
9. F. Sanger, and et al. DNA sequencing with chain-terminating inhibitors Proc. Natl. Acad. Sci. U. S. A. 74 1977 5463 5467
10. D.R. Bentley, and et al. Accurate whole human genome sequencing using reversible terminator chemistry Nature 456 2008 53 59
11. A. Gnirke, and et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing Nat. Biotechnol. 27 2009 182 189
12. Z. Wang, and et al. RNA-Seq: a revolutionary tool for transcriptomics Nat. Rev. Genet. 10 2009 57 63
13. F. Krueger, and et al. DNA methylome analysis using short bisulfite sequencing data Nat. Methods 9 2012 145 151
14. P.J. Stephens, and et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development Cell 144 2011 27 40
15. S.C. Baca, and et al. Punctuated evolution of prostate cancer genomes Cell 153 2013 666 677
16. L.B. Alexandrov, and et al. Signatures of mutational processes in human cancer Nature 500 2013 415 421
17. N. Waddell, and et al. Whole genomes redefine the mutational landscape of pancreatic cancer Nature 518 2015 495 501
18. P.A. Northcott, and et al. Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma Nature 511 2014 428 434
19. A.M. Patch, and et al. Whole-genome characterization of chemoresistant ovarian cancer Nature 521 2015 489 494
20. B.J. Druker, and et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N. Engl. J. Med. 344 2001 1031 1037
21. E.L. Kwak, and et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N. Engl. J. Med. 363 2010 1693 1703
22. M. Talpaz, and et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias N. Engl. J. Med. 354 2006 2531 2541
23. J. Verweij, and et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial Lancet 364 2004 1127 1134
24. A. Hauschild, and et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Lancet 380 2012 358 365
25. K.T. Flaherty, and et al. Improved survival with MEK inhibition in BRAF-mutated melanoma N. Engl. J. Med. 367 2012 107 114
26. J.C. Yang, and et al. Symptom control and quality of life in LUX-lung 3: a Phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations J. Clin. Oncol. 2013 10.1200/JCO.2012.46.1764
27. E.A. Perez, and et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31 J. Clin. Oncol. 29 2011 3366 3373
28. S. Verma, and et al. Trastuzumab emtansine for HER2-positive advanced breast cancer N. Engl. J. Med. 367 2012 1783 1791
29. C. Robert, and et al. Improved overall survival in melanoma with combined dabrafenib and trametinib N. Engl. J. Med. 372 2015 30 39
30. P.A. Janne, and et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer N. Engl. J. Med. 372 2015 1689 1699
31. J.Y. Douillard, and et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer N. Engl. J. Med. 369 2013 1023 1034
32. L.V. Sequist, and et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations J. Clin. Oncol. 31 2013 3327 3334
33. B.J. Druker, and et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N. Engl. J. Med. 355 2006 2408 2417
34. M. Maemondo, and et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N. Engl. J. Med. 362 2010 2380 2388
35. H.A. Yu, and et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers Clin. Cancer Res. 19 2013 2240 2247
36. L.V. Sequist, and et al. Rociletinib in EGFR-mutated non-small-cell lung cancer N. Engl. J. Med. 372 2015 1700 1709
37. D.T. Le, and et al. PD-1 blockade in tumors with mismatch-repair deficiency N. Engl. J. Med. 372 2015 2509 2520
38. C. Bettegowda, and et al. Detection of circulating tumor DNA in early- and late-stage human malignancies Sci. Transl. Med. 6 2014 224ra224
39. S.J. Dawson, and et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer N. Engl. J. Med. 368 2013 1199 1209
40. M. Murtaza, and et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA Nature 497 2013 108 112
41. R.J. Leary, and et al. Development of personalized tumor biomarkers using massively parallel sequencing Sci. Transl. Med. 2 2010 20ra14
42. B.J. Evans, and et al. The FDA and genomic tests - getting regulation right N. Engl. J. Med. 372 2015 2258 2264
43. B. Kaufman, and et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation J. Clin. Oncol. 33 2014 244 250